Drugs.com Clinical Trial ResultsOriginal article
Efzimfotase Alfa Showed Numerical Improvement in Six-Minute Walk Test Achieving Mean Difference of 17.05 Metres vs Placebo in Treatment-Naïve Adolescents and Adults with Hypophosphatasia at Week 25 in HICKORY Phase III Trial
Phase 3negativeefzimfotase alfaNegative
AI Analysis
Summary
Efzimfotase alfa failed to achieve statistical significance in the HICKORY Phase III trial's primary endpoint of six-minute walk test improvement in treatment-naïve adolescents and adults with hypophosphatasia, despite showing a numerical improvement of 17.05 meters versus placebo at Week 25.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Did not achieve statistical significance in primary endpoint (six-minute walk test); demonstrated numerical improvement of 17.05 meters vs placebo at Week 25
Importance:7/10
Sentiment:
-0.60
Phase 3 trialenzyme replacement therapyhypophosphatasiaprimary endpoint missedHICKORY trialadolescents and adults
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on October 11, 2026 6:10 PM